Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480983 | 1.00 | DNM1 (0.44) | DNM1TSHRTHRBFAAHTRPV1 | |
| SCHEMBL19511994 | 1.00 | DNM1 (0.44) | DNM1TSHRTHRBFAAHTRPV1 | |
| SCHEMBL10337322 | 1.00 | DNM1 (0.44) | DNM1TSHRTHRBFAAHTRPV1 | |
| SCHEMBL3458341 | 1.00 | DNM1 (0.44) | DNM1TSHRTHRBFAAHTRPV1 | |
| SCHEMBL1743891 | 1.00 | DNM1 (0.44) | DNM1TSHRTHRBFAAHTRPV1 | |
| SCHEMBL7698918 | 0.98 | DNM1 (0.40) | DNM1TSHRTHRBFAAHTRPV1 | |
| SCHEMBL9014021 | 0.95 | TSHR (0.42) | DNM1TSHRTHRBFAAHTRPV1 | |
| SCHEMBL19511992 | 0.95 | TSHR (0.42) | DNM1TSHRTHRBFAAHTRPV1 | |
| SCHEMBL1900761 | 0.95 | TSHR (0.42) | DNM1TSHRTHRBFAAHTRPV1 | |
| SCHEMBL13279660 | 0.95 | TSHR (0.42) | DNM1TSHRTHRBFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4334319-A1 | 2,8-DIHYDROPYRAZOLO[3,4-B]INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| WO-2024028169-A1 | NOVEL SPECIFICALLY SUBSTITUTED THIOPHENOLIC COMPOUNDS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2024-02-08 | — | — | WO | disclosed |
| US-20240009175-A9 | TETRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2024-01-11 | — | — | US | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230271956-A1 | AMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-08-31 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| EP-4185564-A1 | TRICYCLIC HETEROCYCLES | Merck Patent GmbH (DE) | 2023-05-31 | — | — | EP | disclosed |
| US-20230149371-A1 | TETRAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-05-18 | — | — | US | disclosed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023072974-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | SELVITA S.A. (PL) | 2018-05-03 | — | — | US | disclosed |
| EP-3294728-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | disclosed |
| EP-3294729-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016180537-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
| EP-2105458-A1 | Dispersable polythiophene composition. | Agfa-Gevaert (BE) | 2009-09-30 | — | — | EP | disclosed |
| CN-101467276-A | Liquid crystalline rylene tetracarboxylic acid derivatives and use thereof | MAX PLANCK GESELLSCHAFT (DE) | 2009-06-24 | — | — | CN | disclosed |
| US-20080300329-A1 | Modified Open-Cell Foams, and Method for the Production Thereof | BASF AKTIENGESELLSCHAFT (DE) | 2008-12-04 | — | — | US | disclosed |
| US-20060199885-A1 | Silica-reinforced rubber compounded with an alkoxysilane and a strong organic base | LIN CHENCHY J | 2006-09-07 | — | — | US | disclosed |
| US-3975216-A | Wax-flux composition containing a diester of sulfomalic acid for soldering | CHEVRON RESEARCH COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009175-A9 | TETRAZOLE DERIVATIVES | VHL, BRCA1, POT1 | DNM1 2427/4885TSHR 2558/4885THRB 1494/4885 |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | DNM1 869/4885TSHR 2042/4885THRB 776/4885 |
| US-20230271956-A1 | AMIDE DERIVATIVES | BRCA1, HRAS, PCNA | DNM1 946/4885TSHR 2913/4885THRB 1869/4885 |
| US-20230149371-A1 | TETRAZOLE DERIVATIVES | VHL, BRCA1, POT1 | DNM1 2427/4885TSHR 2558/4885THRB 1494/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | DNM1 808/4885TSHR 2088/4885THRB 950/4885 |
| US-20180118718-A1 | Substituted Quinoxaline Derivatives | BRCA1, NQO2, NQO1 | DNM1 1163/4885TSHR 4313/4885THRB 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.